908 Devices Inc. (NASDAQ:MASS – Get Free Report) Director Christopher Brown sold 30,000 shares of the business’s stock in a transaction dated Wednesday, October 7th. The shares were sold at an average price of $11.89, for a total value of $356,700.00. Following the completion of the transaction, the director owned 745,559 shares in the company, valued at $8,864,696.51. This trade represents a 3.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
908 Devices Stock Up 4.3%
Shares of MASS traded up $0.50 during midday trading on Friday, reaching $12.05. 323,080 shares of the stock were exchanged, compared to its average volume of 336,948. The company has a market cap of $498.07 million, a price-to-earnings ratio of -12.68 and a beta of 0.63. 908 Devices Inc. has a 12-month low of $5.03 and a 12-month high of $13.35. The firm has a 50 day simple moving average of $10.44 and a 200-day simple moving average of $8.60.
908 Devices (NASDAQ:MASS – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The firm had revenue of $16.07 million for the quarter, compared to the consensus estimate of $15.37 million. 908 Devices had a negative return on equity of 12.54% and a negative net margin of 56.96%. Research analysts expect that 908 Devices Inc. will post -0.59 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of brokerages have recently commented on MASS. Wall Street Zen lowered 908 Devices from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Weiss Ratings restated a “sell (d-)” rating on shares of 908 Devices in a report on Friday, August 7th. Canaccord Genuity Group began coverage on 908 Devices in a report on Thursday, September 10th. They set a “buy” rating and a $13.50 price target on the stock. Roth Capital boosted their price objective on shares of 908 Devices from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, Stifel Nicolaus lifted their target price on shares of 908 Devices from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, 908 Devices presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.83.
About 908 Devices
908 Devices Inc is a Boston-based technology company that develops and manufactures handheld and portable chemical detection and analysis instruments. Its products are designed to help users identify and characterize chemical substances in the field, at industrial sites and in laboratory settings without requiring samples to be transported to a centralized facility.
The company’s product portfolio includes the MX908 and related devices for detecting and identifying trace chemicals, explosives, narcotics and other substances; the Xplora platform for field and process analysis; and ZipChip technologies used for rapid, high-resolution separations in life sciences and biopharmaceutical research.
See Also
- Five stocks we like better than 908 Devices
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.
